Orange Book product · Generic (ANDA)
MEDROXYPROGESTERONE ACETATE
MEDROXYPROGESTERONE ACETATE
At a glance
Aug 31, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 31, 2022
3 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
MEDROXYPROGESTERONE ACETATE
Strength
150MG/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
AB
Application
ANDA 212844
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of MEDROXYPROGESTERONE ACETATE
- 2004DEPO-SUBQ PROVERA 104Brand (NDA)
NDA 021583 · PFIZER
- 1992DEPO-PROVERABrand (NDA)
NDA 020246 · PFIZER
- —DEPO-PROVERABrand (NDA)
NDA 012541 · PFIZER
- —PROVERABrand (NDA)
NDA 011839 · PFIZER
- 2023MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 215397 · AMNEAL
- 2023MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 214309 · HIKMA
- 2022MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 212824 · EUGIA PHARMA
- 2019MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 210760 · SUN PHARM
- 2019MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 210761 · SUN PHARM
- 2019MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 210335 · CIPLA
- 2018MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 210227 · XIROMED
- 2017MEDROXYPROGESTERONE ACETATEGeneric (ANDA)
ANDA 077235 · AMPHASTAR PHARMS INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
